RIGEL PHARMACEUTICALS INC
NASDAQ: RIGL (Rigel Pharmaceuticals, Inc.)
Last update: 2 hours ago46.48
-0.38 (-0.81%)
| Previous Close | 46.86 |
| Volume | 246,112 |
| Price / Earnings (Forward) | 11.70 |
| Price / Sales | 3.31 |
| Price / Book | 2.06 |
| 52 Weeks Range |
| Profit Margin | 18.31% |
| Operating Margin (TTM) | 23.95% |
| Diluted EPS (TTM) | 2.09 |
| Quarterly Revenue Growth (YOY) | 80.60% |
| Quarterly Earnings Growth (YOY) | 1,845.90% |
| Total Debt/Equity (MRQ) | 544.23% |
| Current Ratio (MRQ) | 2.20 |
| Operating Cash Flow (TTM) | 35.59 M |
| Levered Free Cash Flow (TTM) | 3.40 M |
| Return on Assets (TTM) | 18.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Rigel Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.25 |
|
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.66% |
| % Held by Institutions | 79.25% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |